Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso for chemotherapy induced nausea and vomiting. It also develops SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-04, which is in preclinical trial development for the treatment of colorectal cancer. The company was founded in 2006 and is based in Tokyo, Japan.
तुलना करने के लिए मीट्रिक्स | 4597 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4597पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −4.6x | −5.2x | −0.5x | |
PEG अनुपात | 0.10 | −0.27 | 0.00 | |
क़ीमत/बुक | 7.7x | 3.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 28.3x | 49.0x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | 192.7% | 45.8% | 54.9% | |
उचित मूल्य अपसाइड | अनलॉक करें | 10.3% | 9.8% | अनलॉक करें |